Skip to main content

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article

Delays in Diagnosis of Axial Spondyloarthritis

Jan 12, 2021

The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular

Read Article

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jan 08, 2021

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
Broadalumab the other IL-17 inhibitor, is FDA approved for psoriasis. The AMVISION-1 & AMVISION-2 ph III trials in psoriatic arthritis showed in 962 PsA pts it was effective w/ week 16 ACR20 of ~46% (vs 21% PBO).

Dr. John Cush RheumNow ( View Tweet)

Jan 06, 2021

Spinal Benefits Seen With Cosentyx in PsA

MedPage Today
Jan 05, 2021

Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.



The primary endpoint of a 20% response on the criteria of the Assessment of Spondyloarthritis International Society (ASAS20) at week

Read Article
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing!
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
Nov 08, 2020

@RheumNow #acr20 abs0876 gender differences AS and nrSpA from 3 RCT IXE trials: F more likely to be older, have more nocturnal BP, peripheral pain&fatigue. M have higher CRP & +HLAB27. Ant uveitis > in M w/AS (23.8% vs. 17.9%) but > common in F w/ nr-axSpA (15.2% vs. 7.1%).

Olga Petryna DrPetryna ( View Tweet)
Nov 07, 2020

Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs.

Robert B Chao, MD doctorRBC ( View Tweet)
Nov 07, 2020
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain.

Dr. Rachel Tate uptoTate ( View Tweet)

Nov 07, 2020
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC ( View Tweet)
Nov 06, 2020

Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366

Dr. Antoni Chan synovialjoints ( View Tweet)

Nov 06, 2020

Secukinumab in Psoriatic Arthritis Patients with Axial Disease

Nov 06, 2020

Results of the MAXIMISE trial show that Secukinumab provided clinical improvement and reduction in inflammatory MRI lesions in patients with psoriatic arthritis and axial disease through week 52. 

Read Article

Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20

Robert B Chao, MD doctorRBC ( View Tweet)

Nov 06, 2020

Industry Abstract Previews - ACR2020

Nov 06, 2020

Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.

Read Article

Spondyloarthritis at ACR Convergence 2020

Nov 05, 2020

There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and abstracts during this meeting. 



Here is a flavour of my read through the topics that are

Read Article

Long-Term Benefits of Ixekizumab in Psoriatic Arthritis

Nov 03, 2020

The SPIRIT-P1 study has demonstrated the safety and efficacy of ixekizumab (an IL-17A antagonist) when given to adults w/ active psoriatic arthritis (PsA), and also demonstrating radiographic protection and improvement in skin outcomes as well. 



This phase 3 study, enrolled biologic-

Read Article
×